Prognostic value of pre-treatment human papilloma virus DNA status in cervical cancer

Chong, Gun Oh; Lee, Yoon Hee; Han, Hyung Soo; Lee, Hyun Jung; Park, Ji Young; Hong, Dae Gy; Cho, Young Lae

doi:10.1016/j.ygyno.2017.11.003

Cited by 26 publications

(41 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, HPV is identified in virtually all cervical cancer and premalignant cervical lesions (high grade intraepithelial lesions/cervical intraepithelial neoplasia grade 2-3 [HSIL/CIN2-3] and adenocarcinoma in situ) [2, 3,4,5,6,7,8]. However, despite the development of highly sensitive tests for molecular detection of HPV in recent years [9,10,11,12,13] and irrespectively of the technique used for HPV detection, a small proportion of cervical cancer are consistently negative for HPV in almost all studies [2, 14,15,16].…”

Section: Introductionmentioning

confidence: 99%

HPV-negative tumors of the uterine cervix

et al. 2019

View full text Add to dashboard Cite

Human papillomaviruses (HPV) are the causative agents of virtually all cervical carcinomas. Nevertheless, a small proportion of cervical cancer are negative for HPV, although the significance of this finding remains unclear. We aimed to provide insight into the differential clinico-pathological characteristics of this unusual subset of HPV-negative cervical cancer. We performed HPV-DNA detection using a highly sensitive PCR test (SPF10) and p16 immunostaining in 214 cervical carcinomas specimens from women treated at the Gynecological Oncology Unit of the Hospital Clinic (Barcelona, Spain) from 2012 to 2015. The clinical and pathological characteristics,

show abstract

Section: Introductionmentioning

confidence: 99%

HPV-negative tumors of the uterine cervix

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Moreover, a recent study found that 8–19% of cases were humanpapillomavirus negative, with an average of 14%, using cytology specimens 14. Our previous study also showed that the high risk human papillomavirus negative rate was 18.5% in pretreatment DNA genotype testing 6. It is important to determine whether these were negative or positive in surgical specimens.…”

Section: Discussionmentioning

confidence: 91%

“…Based on the cohorts in our previous study,6 cervical cancers with a pretreatment negative high risk human papillomavirus DNA genotype test (PANArray HPV genotyping Chip, PANArray, PNNAGENE, Daejeon, Korea, or Anyplex II HPV 28 assay kit, Seegene, Seoul, Korea) on cervicovaginal swab and available resected tumor tissue were included in the current study. Retrospective data collection and analysis were approved by the institutional review board of Kyungpook National University Chilgok Hospital.…”

Section: Methodsmentioning

confidence: 99%

Prevalence, survival outcomes, and clinicopathologic factors associated with negative high risk human papillomavirus in surgical specimens of cervical cancer with pretreatment negative DNA genotype test

Chong

Han

Park

et al. 2019

Int J Gynecol Cancer

Self Cite

View full text Add to dashboard Cite

ObjectiveThe aim of this study was to detect high risk human papillomavirus in cervical cancer with a pretreatment negative high risk human papillomavirus DNA genotype test and to evaluate clinicopathologic characteristics and survival outcomes according to high risk human papillomavirus status.MethodsWe investigated high risk human papillomavirus status in surgical specimens from 30 cases of cervical cancer using polymerase chain reaction. Polymerase chain reaction primers were set to detect the presence of the common L1 and E7 regions of human papillomavirus types 16, 18, 31, 33, 45, 52, and 58. We analyzed the following clinicopathologic parameters to evaluate their relationships with high risk human papillomavirus status: age, histology, stage, tumor size, invasion depth, lymphovascular invasion, and recurrent status.ResultsAmong 30 cases with a pretreatment negative DNA genotype test, high risk human papillomavirus was detected in 12 (40.0%), whereas 18 (60.0%) were negatives. Of 12 high risk human papillomavirus positive cases, 10 (33.3%) were positive for the L1 region, 6 (20.0%) of the 7 types were positive for the E7 region, and 4 (13.1%) were positive for both L1 and E7 regions. According to a multiple logistic regression model, tumor size (odds ratio 7.80; 95% confidence interval 1.476 to 41.216; P=0.0097) and stage (odds ratio 7.00; 95% confidence interval 1.293 to 37.910; P=0.0173) were associated with negative high risk human papillomavirus DNA status. Kaplan–Meier survival plots showed that negative high risk human papillomavirus status was associated with worse disease free survival in contrast with positive high risk human papillomavirus status (P=0.0392).ConclusionsNegative high risk human papillomavirus was found in 60% of cervical cancers with a pretreatment negative DNA genotype test. Moreover, the negative high risk human papillomavirus group was associated with worse survival outcome.

show abstract

“…Genotyping HPV is being incorporated in population screening, and it is used to identify tumoral aggressiveness. Whereas HPV 16 is a marker of high-risk lesion, a better disease-free survival was observed in HPV16 cases, more sensitive to treatment, with a lower rate of growth, and better immune response to virus (9) . Besides genotyping, viral load, viral physical status, and circulating fraction of DNA-HPV are biomarkers that need to be better understood (1,16,20,21) .…”

Section: Cenário Atual Dos Biomarcadores No Câncer Cervical E Na Oncomentioning

confidence: 96%

“…of the transformation zone (LLETZ), loop electrosurgical excision procedure (LEEP) to cold-knife conization (CKC), and sometimes other treatment modalities, as laser or cryosurgery. Incidence among young women has expressive rates, and treatment can relate to severe consequences in the reproductive function, such as fetal consequences of low birth weight, premature birth, and miscarriage (9,10) .…”

mentioning

confidence: 99%

Untitled

J Bras Doenças Sex Transm

View full text Add to dashboard Cite

Cervical cancer (CC) is related to HPV infection and represents the third cause of cancer in women. Annually, more than 500,000 new cases are reported worldwide, with significant death rates. It develops due to genetic and epigenetic alterations that control cell growth and differentiation, and may cause death. These alterations induce uncontrolled cell division and invasion of cervical tissue have severe consequences to women's health (1). CC incidence and mortality drop considerably since the implementation of screening tests and vaccination strategies. Nevertheless, CC continues to have a high incidence, mainly in low-income countries, where these programs do not cover territorial frontiers and there is lack of resources to implement vaccination or screening tests. Oncogenic HPV types reached 25% of cases in Brazil over the last years (2) , and there was no modification on HPV types after four years of the vaccination program, according to Tota et al. (3). Usually, screening tests in Brazil cover women from 25 to 64 years old. According to Teixeira et al. (4) , rates of CC under the age of 25 tend to increase, and women over 64 achieved roughly 20% of CC on research of Brazilian women from two high-income cities. HPV 16 and 18 are the predominant genotypes linked to progression to invasive cancer. HPV uses evasion mechanisms of the immune system in early and late stages of the infection, causing its persistence in cutaneous and mucosal tissues. Its continuous expression of viral proteins E6 and E7 contribute to disease progression (5). Starting lesions are well defined and classified into cervical intraepithelial neoplasm 1, 2, and 3, with grade 3 being the highest level of evolution. Factors such as age, smoking, sexually transmitted disease, long-term oral contraceptive use, and parity are associated to a higher risk of cervical cancer development (6,7). Many CIN 1, 2, and some CIN 3 lesions spontaneously revert. Even though, treatment is still needed, because they have high chances to progress (8) .

show abstract

Prognostic value of pre-treatment human papilloma virus DNA status in cervical cancer

Cited by 26 publications

References 24 publications

HPV-negative tumors of the uterine cervix

HPV-negative tumors of the uterine cervix

Prevalence, survival outcomes, and clinicopathologic factors associated with negative high risk human papillomavirus in surgical specimens of cervical cancer with pretreatment negative DNA genotype test

Untitled

Contact Info

Product

Resources

About